TABLE 2:

Case reports, series and cohort studies detailing use of ICI in the peritransplantation setting for HCC therapy.

Pre-LT	Author	Age/Sex	ICI regimen	Therapy Prior to/with ICI	ICI duration of Treatment	ICI Completion to Transplant (m)	Rejection	Other Outcomes
	Nordness et al. 2020	65 M	nivolumab	Hepatectomy Sorafenib TARE TACE	2 years	8 days	Yes	- Partial remission pre-LT - Fatal hepatic necrosis
	Schwacha-Eipper 2020	62 M	nivolumab	Sorafenib Regorafenib	34 cycles	6 weeks	No	-Partial remission pre-LT
	Chen et al 2021	39 M	toripalimab	Hepatectomy TACE Sorafenib Lenvatinib Ablation	10 cycles	93 days	Yes	-Fatal acute hepatic necrosis
	Kang et al. 2022	14 M	pembrolizumab	Cisplatin/Doxorubicin/Dexrazoxane Hepatectomy TACE	9 weeks	138 days	No	-Hepatic artery dissection -Graft loss
	Schnickel et al. 2022	61F	nivolumab	n/a	18 months	5 weeks	Yes	-Hepatic necrosis -Graft loss
		65M	nivolumab	n/a	8 months	10 days	Yes	-Hepatic necrosis
		71 M	nivolumab	n/a	8 months	3 months	No	n/a
		65 F	nivolumab	n/a	12 months	4 months	No	n/s
		68M	nivolumab	n/a	12 months	6 months	No	-Cholestasis -Death
	Abdelrahim et al. 2024	64 M	atezolimumab+bevacimumab	Radiation	4 months	4 months	No	-Recurrence
		61 M	nivolumab	TARE Hepatectomy Sorafenib	8 months	8 weeks	No	n/a
		58 M	atezolimumab+bevacimumab	TARE Lenvatinib TACE Carbonzatinib	3 months	6 months	No	-Recurrence
		61 M	nivolumab atezolimumab+ bevacimumab	Lenvatinib	1 month 3 months	2 months	No	n/a
		68 M	atezolizumab + bevacimumab	TARE TACE Ablation Lenvatinib	16 months	36 months	No	-Chronic respiratory failure -Sustained bacteremia and septic shock
		59 M	nivolumab ipilimumab	Hepatectomy Ablation TACE Radiation	1 months	41 months	No	-ICI associated hepatotoxicity -Mesh related complications
Post-LT	Author	Age/Sex	ICI regimen	Other Post-LT Therapy	ICI duration of Treatment	Transplant to ICI Initiation Duration (m)	Rejection	Other Outcomes
	Varkaris et al. 2017	70 M	pembrolizumab	Sorafenib Chemoradiation Capecitabine	4 months	8 years	No	-Disease progression
	De Toni et al. 2017	41 M	nivolumab	TACE Ablation	15 cycles	11 months	Yes	-Disease progression
	Friend et al. 2017	20 M	nivolumab	Sorafenib Capecitabine	2 weeks	3 years	Yes	-Fatal acute graft rejection
		14 M	nivolumab	Sorafenib Capecitabine	1 week	3 years	Yes	-Fatal acute graft rejection
	Rammohan et al. 2018	57 M	pembrolizumab	Sorafenib	10 months	4 years	No	-Partial remission
	DeLeon et al. 2018	56 M	nivolumab	Sorafenib	1.2 months	2.7 years	No	-Disease progression
		55 M	nivolumab	Sorafenib	1.1 months	7.8 years	No	-Disease progression
		34 F	nivolumab	Sorafenib	1.3 months	3.7 years	No	-Disease progression
		63 M	nivolumab	Sorafenib	0.3 months	1.2 years	No	-Multiorgan failure
		68 M	nivolumab	Sorafenib	0.9 months	1.1 years	Yes	n/a
	Gassmann et al. 2018	53 F	nivolumab	Sorafenib	1 week	2 years	Yes	-Fatal severe graft rejection
	Amjad et al. 2019	62 F	nivolumab	TACE Radiation	6 months	1.3 Years	No	-Complete remission
	Kumar et al. 2019	64 M	nivolumab	Sorafenib	1 week	2 years	Yes	-n/a
	Pandey et al. 2020	52F	ipilumumab	Ablation Sorafenib	13 months	7.5 years	No	-Complete remission
	Al Jarroudi O. 2020	70 M	nivolumab	Sorafenib Gemcitabine Oxaliplatin Regorafenib	8 weeks	3 years	Yes	-Disease progression
		62 F	nivolumab	Sorafenib Regorafenib 5 fluorouracil/ Oxaliplatin	10 weeks	unknown	No	-Disease progression
		66 M	nivolumab	Sorafenib Regorafenib	12 weeks	5 years	No	-Disease progression
	Anugwom et al. 2020	62 M	nivolumab	Sorafenib Carboplatin/Gemcitabine 5 fluorouracil/ oxaliplatin Radiation	2 months	1 year	Yes	-Immune hepatitis